{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:30:15Z","timestamp":1792639815541,"version":"4.5.0"},"reference-count":38,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T00:00:00Z","timestamp":1127174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Forty\u2010four patients with relapsed or refractory aggressive histology non\u2010Hodgkin lymphoma (NHL) (diffuse large B cell,\n                    <jats:italic>n<\/jats:italic>\n                    \u2003=\u200323; peripheral T cell,\n                    <jats:italic>n<\/jats:italic>\n                    \u2003=\u20035; transformed B cell,\n                    <jats:italic>n<\/jats:italic>\n                    \u2003=\u200316) proceeded to allogeneic stem cell transplant (allo\u2010SCT) between 1987 and 2003. Median age at transplant was 40\u2003years (range 19\u201356\u2003years). At the time of transplant, 35 were chemosensitive and nine were chemorefractory. Thirty\u2010three patients had matched sibling donors and 11 had unrelated donors. Forty\u2010two patients (95%) received radiation\u2010based conditioning regimens. Event\u2010free survival (EFS) and overall survival (OS) at 5\u2003years was 43% [95% confidence interval (CI): 27\u201358%] and 48% (95% CI: 32\u201363%) respectively. Treatment\u2010related mortality was 25% at 1\u2003year. Grade III\u2013IV acute graft\u2010\n                    <jats:italic>versus<\/jats:italic>\n                    \u2010host disease (GVHD) was the only significant variable affecting OS and EFS, and had a negative impact. Chronic GVHD did not influence survival. Lymphoma relapse &lt;12\u2003months after initial therapy predicted for increased risk of relapse post\u2010transplant (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030\u00b702). Patients with chemorefractory lymphoma were not at increased risk of relapse (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030\u00b720) with four of nine patients remaining alive without disease 12\u2013103\u2003months post\u2010transplant. In conclusion, allo\u2010SCT for relapsed or refractory aggressive histology NHL results in long\u2010term EFS and OS of 40\u201350%. Patients with chemorefractory disease can have a durable remission post\u2010transplant.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2141.2005.05755.x","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T04:23:15Z","timestamp":1127190195000},"page":"223-230","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Allogeneic haematopoietic stem\u2010cell transplantation for relapsed and refractory aggressive histology non\u2010Hodgkin lymphoma*"],"prefix":"10.1111","volume":"131","author":[{"given":"Richard T.","family":"Doocey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia L.","family":"Toze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Nevill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna L.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna E.","family":"Hogge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julye C.","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H.","family":"Nantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,9,30]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"247","article-title":"Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft\u2010versus\u2010host disease. Committee of the International Bone Marrow Transplant Registry","volume":"4","author":"Atkinson K.","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700781"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.054"},{"key":"e_1_2_6_5_1","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone P.P.","year":"1971","journal-title":"Cancer Research"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02705.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.433"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.75"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.050"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20587"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01666.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304083281404"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0231"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3264"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008263602334"},{"key":"e_1_2_6_18_1","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe E.S.","year":"2001"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.3.649.649"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_21_1","first-page":"190a","article-title":"Long term remission and low mortality achieved with cisplatin, fludarabine, cytarabine nonablative preparative regimen and allogeneic stem cell transplantation (AST) for histologically aggressive non Hodgkins lymphoma (NHL)","volume":"98","author":"Khouri I.","year":"2001","journal-title":"Blood"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703875"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001623694"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1105"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3776"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702392"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/2.suppl_1.17"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703891"},{"key":"e_1_2_6_29_1","doi-asserted-by":"crossref","first-page":"157a","DOI":"10.1182\/blood.V104.11.157.157","article-title":"First analysis of the completed Mabthera International (MinT) trial in young patients with low\u2010risk diffuse large B\u2010cell lymphoma (DLBCL): addition of rituximab to a CHOP\u2010like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI\u2003=\u20030 and no bulk disease","volume":"104","author":"Pfreundschuh M.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.7.1587.1587"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_6_32_1","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka D.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.4.1050.1050"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-11-0107"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.137"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704233"},{"key":"e_1_2_6_37_1","first-page":"2813a","article-title":"Durable progression free survival (PFS) following non\u2010myeloablative bone marrow transplantation (BMT) for chemorefractory diffuse large B cell lymphoma (B\u2010LCL)","volume":"98","author":"Spitzer T.","year":"2001","journal-title":"Blood"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.727"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2005.05755.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2005.05755.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T21:17:51Z","timestamp":1697404671000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2005.05755.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,30]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.1111\/j.1365-2141.2005.05755.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05755.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,30]]},"assertion":[{"value":"2005-09-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}